About this episode

This episode discusses how patient preference data can influence the approval of high-risk medical devices despite serious adverse events.

Imagine you are running a pivotal clinical trial for a novel implant. The data comes back, and it is rough: 80% of your patients have suffered a serious adverse event, and 40% have developed acute kidney injury. If you are sitting in the regulatory or risk management seat, you are likely drafting the project’s post-mortem. In a traditional risk management paradigm, you are preparing to tell the executive team that the device failed to meet any traditional safety threshold. But what if the FDA didn’t just approve this device, but approved it specifically because the sponsors mathematically proved that patients were willing to tolerate a higher level or risk to gain access to this device? This scenario completely dismantles the way the MedTech industry has historically viewed safety and effectiveness. As professionals, we are trained to treat clinical thresholds as objective, immutable laws of physics—a line in the sand where an adverse event rate either passes or fails. However, with the FDA’s finalized guidance issued on March 30, 2026, safety is no longer just a raw numerical threshold; it is now a quantifiable variable relative to the validated preference of the end user. So…

People in this episode

Host: Dr. Naveen Agarwal

Topics covered

• patient preference data
• risk management
• medical device approval
• clinical trials
• safety thresholds

Keywords

• patient preference
• risk management
• FDA approval
• clinical trials
• adverse events
• medical devices
• safety thresholds

Mentioned in this episode

Organizations: FDA

More episodes of Let's Talk Risk! with Dr. Naveen Agarwal

• LTR 152: Omar Al Kalaa on Telesurgery and the Future of Remotely Controlled Medical Systems · April 24, 2026 · 36 min
• LTR 151: Sarai Pahla on Managing Supply Chain Disruption Risk in Life Sciences · April 17, 2026 · 26 min
• LTR 150: Jonathan Kendler on Rethinking Human Factors Engineering for AI/ML-Enabled Devices · April 3, 2026 · 29 min
• LTR 149: Lavanya Ramnath on Risk Analysis, IDE Strategy, and Patient-Centered Design · March 27, 2026 · 29 min
• LTR 148: Chris Daly on Companion Diagnostics, AI, and FDA’s Evolving Approach · March 20, 2026 · 29 min
• LTR 147: Richard Matt on Bringing Benefit–Risk Upstream in Design and Development · March 13, 2026 · 27 min

Explore listener stats, chart rankings, contacts and more on the Let's Talk Risk! with Dr. Naveen Agarwal podcast page.